Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
FDA, schizophrenia
FDA approves 1st new drug to treat schizophrenia in more than 30 years
This drug takes the first new approach to schizophrenia treatment in decades," Farchione continued. "This approval offers a new alternative to the antipsychotic medications peo
Regeneron-Sanofi Drug Wins FDA Approval To Treat COPD
Shares of Regeneron Pharmaceuticals and Sanofi edged higher Friday after their drug to treat chronic obstructive pulmonary disease received approval from the Food and Drug Administration.
New schizophrenia drug gets FDA approval, taking novel approach to treating brain disorder
On Thursday, the U.S. Food and Drug Administration approved COBENFY, an oral medication that marks the first new class of drugs for schizophrenia in more than 30 years.
Sanofi-Regeneron's Dupixent wins FDA's nod for 'smoker's lung'
The U.S. Food and Drug Administration has approved Sanofi and Regeneron's blockbuster drug Dupixent for patients with a chronic lung disease, commonly known as "smoker's lung", the companies said on Friday.
Regeneron, Sanofi Get FDA OK for Dupixent to Treat COPD
Regeneron Pharmaceuticals and Sanofi have won FDA expanded approval of their blockbuster anti-inflammatory drug Dupixent in chronic obstructive pulmonary disease.
Regeneron/ Sanofi granted FDA label expansion for Dupixent in COPD
Regeneron (REGN) and Sanofi's (SNY) asthma therapy Dupixent receives FDA approval for label expansion in treating certain patients with COPD. Read more here.
Regeneron, Sanofi blockbuster Dupixent wins FDA approval for COPD
Dupixent, commonly used to treat eczema and asthma, was cleared for a subset of patients with chronic obstructive pulmonary disease.
US FDA approves Sanofi-Regeneron's Dupixent for 'smoker's lung'
Sanofi recorded 10.72 billion euros ($11.94 billion) in sales for Dupixent in 2023, which includes Regeneron's share. Analysts on average expect Dupixent, by far Sanofi's best-selling drug, to generate more than 21 billion euros in sales in 2030,
Regeneron And Sanofi Snag Their $6 Billion-Potential COPD Approval For Dupixent
Regeneron stock XX on XX after the company won FDA approval for Dupixent in chronic obstructive pulmonary disease, or COPD.
9h
The FDA Is Launching New Traceability Rules for Added Food Safety — and Everyone Is Confused
On January 20, 2026, the Food and Drug Administration's (FDA) new traceability rules — dubbed the Food Traceability Final ...
2d
on MSN
FDA Approves the First New Schizophrenia Drug in Decades
Developed by Karuna Therapeutics, which was subsequently acquired by Bristol Myers Squibb, the drug works in an entirely ...
2d
FDA issues recall notices for two brands of pet food over salmonella and listeria contamination
Pet owners are advised to throw away the at-risk products safely, so pets and children can't access and ingest them ...
4d
FDA Warns Recalled Dog Food Should Be 'Thrown Out or Destroyed'
The pet food was found to be contaminated with bacteria that can cause illness and even death in pets and humans.
STAT
1d
The FDA is ‘making sandwiches,’ ‘breakfast salad’ in DC, and what keeps us from choking on food
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. In a new ...
3d
These 2 brands of pet food may be contaminated with salmonella and listeria, FDA says
The U.S. FDA issued warnings for ANSWERS Pet Food and Darwin's Natural Pet Products as they contain Salmonella and Listeria.
Investopedia
19d
Food and Drug Administration (FDA): What It Is and Does
Her expertise is in personal finance and investing, and real estate. The
Food and Drug Administration
(
FDA
) is a government agency that is responsible for the promotion and protection of public ...
Business Wire
1d
U.S. Food and Drug Administration Approves Bristol Myers Squibb’s COBENFY™ (xanomeline and trospium chloride), a First-In-Class Muscarinic Agonist for the Treatment of ...
U.S. FDA Approves Bristol Myers Squibb’s COBENFY, a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback